Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially happened last week, though no public announcements were made. Rampart also ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...